Interpace Biosciences, Inc.
Interpace Biosciences, Inc. Fundamental Analysis
Interpace Biosciences, Inc. (IDXG) shows strong financial fundamentals with a PE ratio of 0.35, profit margin of 63.46%, and ROE of 4.85%. The company generates $0.0B in annual revenue with strong year-over-year growth of 16.69%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 68.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze IDXG's fundamental strength across five key dimensions:
Efficiency Score
ExcellentIDXG demonstrates superior asset utilization.
Valuation Score
ExcellentIDXG trades at attractive valuation levels.
Growth Score
ModerateIDXG shows steady but slowing expansion.
Financial Health Score
ExcellentIDXG maintains a strong and stable balance sheet.
Profitability Score
ModerateIDXG maintains healthy but balanced margins.
Key Financial Metrics
Is IDXG Expensive or Cheap?
P/E Ratio
IDXG trades at 0.35 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, IDXG's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Interpace Biosciences, Inc. at 0.39 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.55 times EBITDA. This is generally considered low.
How Well Does IDXG Make Money?
Net Profit Margin
For every $100 in sales, Interpace Biosciences, Inc. keeps $63.46 as profit after all expenses.
Operating Margin
Core operations generate 10.55 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.85 in profit for every $100 of shareholder equity.
ROA
Interpace Biosciences, Inc. generates $72.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Interpace Biosciences, Inc. produces operating cash flow of $7.78M, showing steady but balanced cash generation.
Free Cash Flow
Interpace Biosciences, Inc. generates strong free cash flow of $7.10M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.60 in free cash annually.
FCF Yield
IDXG converts 81.82% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.35
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.22
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.94
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
4.85
vs 25 benchmark
ROA
Return on assets percentage
0.73
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How IDXG Stacks Against Its Sector Peers
| Metric | IDXG Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.35 | 28.45 | Better (Cheaper) |
| ROE | 484.95% | 763.00% | Weak |
| Net Margin | 63.46% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.94 | 2795.60 | Neutral |
| ROA | 72.63% | -16588.00% (disorted) | Strong |
IDXG outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Interpace Biosciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
66.41%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
121.48%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
120.93%
Industry Style: Defensive, Growth, Innovation
High Growth